iRhythm’s Q2 earnings soar with seven straight quarters of 20% growth, fueled by strong Zio demand, global expansion, and rising margins. Their big move? Acquiring VitalConnect to supercharge cardiac monitoring innovation, adding 30-day multi-vital tracking and live viewing to their arsenal. This strategic play targets earlier patient intervention in primary care and beyond, using AI to flag arrhythmia risks sooner—boosting outcomes and cutting costs. Plus, regulatory wins like FDA clearance for their new algorithm, resolution of a $50M litigation, and a contained cybersecurity incident all reinforce their path forward: relentless growth, smarter tech, and a solid operational foundation in the booming cardiac monitoring space.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
